Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
D DERMATOLOGICALS
D01 ANTIFUNGALS FOR DERMATOLOGICAL USE
D01B ANTIFUNGALS FOR SYSTEMIC USE
D01BA Antifungals for systemic use
D01BA03 Fosravuconazole
D10762 Fosravuconazole L-lysine ethanolate (JAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
629 Miscellaneous
6290 Miscellaneous
D10762 Fosravuconazole L-lysine ethanolate (JAN)
Drug groups [BR:br08330]
Antifungal
DG01523 Triazole antifungal
DG02844 Ravuconazole
D10762 Fosravuconazole L-lysine ethanolate
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG02844 Ravuconazole
D10762 Fosravuconazole L-lysine ethanolate
Drug classes [BR:br08332]
Antifungal
DG01523 Triazole antifungal
D10762 Fosravuconazole L-lysine ethanolate
Antimicrobials [BR:br08307]
Antifungals
Ergosterol biosynthesis inhibitor
Triazole
D10762 Fosravuconazole L-lysine ethanolate (JAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10762
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10762
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10762
Drug groups [BR:br08330]
Antifungal
DG01523 Triazole antifungal
DG02844 Ravuconazole
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG02844 Ravuconazole
Antimicrobials abbreviations [BR:br08327]
Antifungals
Ergosterol biosynthesis inhibitor
Triazole
DG02844 Ravuconazole